Hydrazono-malonitriles
    17.
    发明授权
    Hydrazono-malonitriles 失效
    肼类 - 丙二醛

    公开(公告)号:US07544684B2

    公开(公告)日:2009-06-09

    申请号:US11497235

    申请日:2006-08-02

    CPC classification number: C07D403/12 C07D237/04

    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

    Abstract translation: 其中R 1,R 2,R 3,R 3'和R 4具有权利要求1中给出的含义的式(I)的肼基 - 丙腈衍生物作为磷酸二酯酶IV抑制剂起作用,可用于治疗骨质疏松症,恶病质,恶病质,动脉粥样硬化, 类风湿关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫性疾病,心肌疾病和艾滋病。

    Aryl oximes
    18.
    发明授权
    Aryl oximes 失效
    芳肟

    公开(公告)号:US07470687B2

    公开(公告)日:2008-12-30

    申请号:US11429181

    申请日:2006-05-08

    CPC classification number: C07D401/12 C07D237/04 C07D403/12

    Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

    Abstract translation: 式(I)的芳基肟衍生物,其中R 1,R 2,R 3,X和B如权利要求1所定义,作为磷酸二酯酶IV抑制剂,可用于治疗骨质疏松症,肿瘤,恶病质,动脉粥样硬化,类风湿 关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫疾病,心肌疾病和艾滋病。

    2-Aminoalkyl-thieno[2,3-d]pyrimidines
    19.
    发明授权
    2-Aminoalkyl-thieno[2,3-d]pyrimidines 失效
    2-氨基烷基 - 噻吩并[2,3-d]嘧啶

    公开(公告)号:US07259168B2

    公开(公告)日:2007-08-21

    申请号:US10312767

    申请日:2001-06-28

    CPC classification number: C07D495/04

    Abstract: The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.

    Abstract translation: 本发明涉及通式(I)的2-氨基甲基噻吩并[2,3-d]嘧啶,其中R 1至R 6基团具有所述含义 在文中。 化合物显示磷酸二酯酶V抑制,并且可用于治疗心血管系统的病症和治疗效力障碍。

Patent Agency Ranking